PGEN

Precigen is a newly-commercial biotech whose entire near-term case rests on one product: Papzimeos (PRGN-2012), which won full FDA approval in August 2025 as the first and only approved therapy for adult RRP — a genuine, de-risking milestone (no confirmatory trial required, 51% durable complete response in the pivotal study). That is the bull case, and it is real. But the financials around it are alarming. FY2025 revenue was just $9.68M (up 147% off a tiny base), while the net loss nearly doubled to -$251M and operating cash flow was -$87.8M. The company itself warns it 'will incur losses and negative cash flows from operating activities for the foreseeable future' and that commercialization expenses will 'increase substantially.'

The balance sheet cannot comfortably fund that. Cash and equivalents stood at only $30.2M against an $87.8M annual operating burn — well under six months of runway at the FY2025 rate, just as the company is ramping its most expensive phase (commercial launch). Long-term debt of $93.2M dwarfs stockholders' equity of $20.9M (liabilities/equity 6.44x), equity fell 46% YoY, and the accumulated deficit is $2.34B. Shares outstanding already rose 20.4% in a year, and management flags substantial future capital needs — meaning near-certain, possibly dilutive or debt-laden financing on whatever terms the market dictates. The lone profitable year (FY2022) was an artifact of the TransOva divestiture gain ($94.7M), not operations.